Otsuka’s Lupkynis receives NICE green light
Recommendation applies across England and Wales and the treatment is available now
Read More
Tag: Lupkynis
Otsuka receives vital Lupkynis MHRA authorisation
Therapy represents first oral calcineurin-inhibitor treatment for active lupus nephritis in adults
Read More
Aurinia receives positive CHMP opinion for Lupkynis
Therapy effectively treats adults with active lupus nephritis in Europe
Read More
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
